AAS
CRSP icon

Ameritas Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Ameritas Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.5K Buy
+1,018
New +$53.7K ﹤0.01% 1232
2025
Q4 		– Sell
-143
Closed -$9.27K – 1169
2025
Q3 		$9.27K Hold
143
– – ﹤0.01% 1688
2025
Q2 		$6.96K Buy
+143
New +$5.53K ﹤0.01% 2144
2023
Q2 		– Sell
-300
Closed -$14.2K – 946
2023
Q1 		$14.2K Buy
+300
New +$14.6K ﹤0.01% 1777

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ameritas Advisory Services's CRSP Position: Q2 2026 in Review

Ameritas Advisory Services opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 1,018 shares worth $55.5K. The stake represents ﹤0.01% of the portfolio and ranks #1232 among its holdings. This is a return to the name: Ameritas Advisory Services previously reported a position in CRSP as recently as Q3 2025.

Ameritas Advisory Services first reported a position in CRSP in Q1 2023 and has held it in 4 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Ameritas Advisory Services held 1,018 shares of CRISPR Therapeutics worth $55.5K as of Q2 2026.
  • CRISPR Therapeutics was a new Ameritas Advisory Services position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q2 2026, its #1232 holding.
  • Ameritas Advisory Services first reported a position in CRISPR Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.